“The Evaluation of SATB2 As a Diagnostic Immunohistochemical Marker of Colorectal Adenocarcinoma in Comparison With Non-Colorectal Adenocarcinomas”. 2023. Journal of Pharmaceutical Negative Results, February, 2280-89. https://doi.org/10.47750/pnr.2023.14.02.278.